1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Thrombin

Thrombin

Thrombin is a Na+-activated, serine protease which is activated by the enzymatic cleavage of two sites on prothrombin by activated Factor X. Thrombin exists in two allosteric forms, slow (S) and fast (F), target toward anticoagulant and procoagulant activities.

Thrombin is the main effector protease in primary hemostasis by activating platelets and plays a key role in secondary hemostasis. Besides its well-known functions in hemostasis, thrombin also plays a role in various non-hemostatic biological and pathophysiologic processes, predominantly mediated through activation of protease-activated receptors (PARs). PAR-1, PAR-3, and PAR-4 are cleaved by thrombin, whereas PAR-2 is cleaved by trypsin. Thrombin also plays a crucial role in the migration and metastasis of human cancer cells.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N15271
    Oxopurpureine
    Oxopurpureine is an oxoaporphine with antiplatelet aggregation activity. Oxopurpureine inhibits collagen, thrombin and arachidonic acid-induced platelet aggregation and can be utilized in relevant research.
    Oxopurpureine
  • HY-19219
    BMS-189664
    Inhibitor
    BMS-189664 is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC50 of 0.046 μM. BMS-189664 can be used for arterial and venous thrombosis research.
    BMS-189664
  • HY-161867
    Platelet aggregation-IN-1
    Platelet aggregation-IN-1 (Compound 10e) is an inhibitor for platelet aggregation, that inhibits 100% thrombin-induced platalet aggregation at 50 μM.
    Platelet aggregation-IN-1
  • HY-116913
    Moxicoumone
    Inhibitor
    Moxicoumone is an anticoagulant.
    Moxicoumone
  • HY-15759A
    Napsagatran hydrate
    Inhibitor
    Napsagatran hydrate is a novel and specific thrombin inhibitor.
    Napsagatran hydrate
  • HY-19660
    Inogatran
    Inhibitor
    Inogatran (H-314-27) is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.
    Inogatran
  • HY-10275
    Atecegatran
    Inhibitor
    Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a Ki of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC50 ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders.
    Atecegatran
  • HY-10271
    Flovagatran sodium
    Inhibitor
    Flovagatran (TGN 255) sodium is a potent and reversible thrombin inhibitor (Ki: 9 nM). Flovagatran sodium can be used in the research of arterial and venous thrombosis.
    Flovagatran sodium
  • HY-N6864R
    Isovanillic acid (Standard)
    Inhibitor
    Isovanillic acid (3-Hydroxy-4-methoxybenzoic acid) is a phenolic acid isolated from isolated from Scrophularia ningpoensis, with anti-thrombotic activity.
    Isovanillic acid (Standard)
  • HY-P0019B
    Z-Gly-Gly-Arg-AMC TFA
    Substrate
    Z-Gly-Gly-Arg-AMC TFA is the TFA salt form of Z-Gly-Gly-Arg-AMC (HY-P0019). Z-Gly-Gly-Arg-AMC TFA is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP) (Ex/Em = 390/480 nm).
    Z-Gly-Gly-Arg-AMC TFA
  • HY-N13955
    Bacithrocin B
    Inhibitor
    Bacithrocin B is a thrombin inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC50s of 84 μM, 17 μM, 1.7 μM, and 0.02 μM, respectively.
    Bacithrocin B
  • HY-149397
    FXIIa-IN-2
    Inhibitor
    FXIIa-IN-1-IN-2 (Compound 21) is a Factor XIIa inhibitor (Kiapp: 62.2 nM). FXIIa-IN-1-IN-2 can be used for research of thrombosis.
    FXIIa-IN-2
  • HY-106691
    Pirmagrel
    Inhibitor
    Pirmagrel is a thrombin synthetase inhibitor. Pirmagrel has inhibitory effects on thrombin secretion stimulated by lipopolysaccharide (HY-D1056).
    Pirmagrel
  • HY-105392
    LB30057
    Inhibitor
    LB30057 (CI-1028) is an orally active selective thrombin inhibitor with an IC50 value of 0.38 nM for human thrombin. LB30057 can be used in the study of the thrombus model.
    LB30057
  • HY-P0316
    TP508
    Antagonist
    TP508 is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 activates endothelial cells and stem cells to revascularize and regenerate tissues.
    TP508
  • HY-U00370
    Thrombin inhibitor 1
    Inhibitor
    Thrombin inhibitor 1 is a potent thrombin inhibitor (Ki=0.66 nM, 2xaPTT=0.43 μM).
    Thrombin inhibitor 1
  • HY-U00039
    Desethyl KBT-3022
    Desethyl KBT-3022 is the main active metabolite of the new antiplatelet agent, KBT-3022.
    Desethyl KBT-3022
Cat. No. Product Name / Synonyms Application Reactivity